A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries
Sponsor: Vertex Pharmaceuticals Incorporated
Listed as NCT06887972, this PHASE4 trial focuses on Acute Pain and remains completed. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE4
-
May 2025 — Nov 2025 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE4
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .